All In Biotech

Drug Trial Radar · NCT00478556

Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Last checked: Nov 19, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Aug 2007

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GE Healthcare
First posted
May 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.

Conditions

  • Healthy

Interventions

  • OmnipaqueDrug

    Oral CT contrast

  • GastroviewDrug

    Oral CT contrast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Preferred Contrast AgentTime frame: 1 Day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Kirklin Clinic

    Birmingham, Alabama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.